Chemify

1001 AI is a deep-tech artificial intelligence startup that develops AI infrastructure and decision-automation platforms for large-scale industries. The company focuses on using AI to help organizations analyze operational data, automate complex decisions, and improve efficiency in critical sectors such as aviation, logistics, construction, and energy.

MDOTM develops AI-driven investment solutions for institutional investors. The company offers Sphere, an AI platform that provides investment insights, portfolio construction and rebalancing at scale, and automated portfolio commentaries. Its technology supports asset and wealth managers, banks, insurers, pension funds, family offices, and other financial institutions. MDOTM also provides portfolio advisory and asset allocation services that integrate AI models into existing investment processes.

Whiteshield is an advisory firm that offers public policy consulting, AI analytics, and SaaS solutions.

Nscale is an AI GPU cloud platform that provides scale computing to the generative AI market. It develops AI-ready data centers, deploys GPU infrastructure, and delivers AI cloud services. Its AI private cloud platform supports the entire generative AI lifecycle, enabling developers to run and train AI models. It also provides bare metal and virtualized GPU nodes, Kubernetes-native services (NKS), AI workload scheduling empowered by SLURM, and advanced serverless and dedicated inferencing options.

NexGen Cloud specializes in sustainable cloud Infrastructure as a Service solutions, with a focus on High-Performance Computing and GPU infrastructure. It provides GPU as a Service through its Hyperstack platform, catering to businesses in need of intensive computing resources. As an Elite NVIDIA Partner, NexGen Cloud allows customers to access GPU-accelerated servers for significant annual returns. The company prioritizes a customer-centric approach, offering secure and sustainable cloud services. NexGen Cloud also seeks out technology partnerships and investments to establish itself as a prominent player in the European cloud IaaS market.

Automata is a company that specializes in automation and supports the life sciences industry in accelerating innovation, diagnosis, and discovery processes on a larger scale. The company offers robotic automation solutions specifically designed for laboratories within the life science field, allowing them to effectively expand and achieve faster outcomes.

Kalipso automates regulatory compliance with smart mapping and policy update tools.

Houdini Bio develops computational synthetic biology tools that redesign DNA sequences and gene constructs for more effective genetic medicines. The company focuses on re-engineering and optimizing DNA constructs to address performance and scalability constraints in complex therapeutics. Its technology applies computational biology methods to improve expression characteristics and manufacturing properties of genetic medicine assets. Houdini Bio works with partners developing next-generation genetic therapies who seek to enhance therapeutic index and production output. Its core offering centers on a DNA redesign engine that enables systematic exploration of sequence space to generate constructs with improved functional profiles. The company positions its capabilities for use in biopharmaceutical research and development workflows for genetic medicines. Houdini Bio concentrates on supporting organizations working on advanced genetic therapeutics that require improved construct design and manufacturability.

Behavox is an Artificial Intelligence company on a mission to build cutting-edge AI systems that safeguard businesses and enhance human productivity. As the world's foremost provider of AI-powered archiving, compliance, and security solutions, we are trusted by leading organizations to secure their text and voice communications data, and monitor a broad range of regulatory, conduct, and insider threat risks. Founded in 2014, Behavox is headquartered in London, with offices worldwide, including in New York City, Montreal, Seattle, Singapore, and Tokyo.

FinalDose develops programmable DNA therapeutics that target diseases at the level of their underlying genetic code. The company focuses on a DNA drug platform that uses engineered fusion proteins to scan cellular genomes for predefined diseased DNA sequences. When the therapeutic recognizes its programmed target, it undergoes a structural change that activates a cellular kill switch to eliminate the diseased cell while sparing neighboring healthy tissue. This approach aims to address disease drivers that are considered undruggable by conventional protein-targeting methods. FinalDose initially applies its platform to cancers driven by complex mutations, using established human genetics knowledge to guide target selection and reduce research and validation cycles.

Dayjob is an AI-driven logistics automation platform that builds autonomous AI workers to manage and execute real-time transport operations.

Inth offers an observability platform that provides open-source consent management standard for users and AI agents.